Allergan to Showcase New Data at ARVO

Source: Allergan

Allergan will present new data at the Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) to be held in Vancouver, British Columbia from April 28 – May 2.

Data will include three paper presentations on the company’s ophthalmology pipeline including new findings evaluating Abicipar in patients with wet age-related macular degeneration (AMD) and brimonidine drug delivery system (DDS) in patients with geographic atrophy secondary to age-related macular degeneration (AMD). Additional company-sponsored data for the investigational Bimatoprost sustained release (SR), will also be presented including data analysis from a phase 1/2, 24-month, prospective, multicenter, dose-ranging study of 75 open-angle glaucoma patients, which evaluated whether continuous drug release with Bimatoprost SR reduces visual field progression rates compared with topical dosing over 24 months.

“This new data in retina and glaucoma underscores our commitment to research and innovation aimed at finding new treatments for the eye care community,” Yehia Hashad, MD, Senior Vice President, Head of Global Clinical Development, Allergan, said in a company news release. “At ARVO, we look forward to presenting data from our late-stage products for age-related macular degeneration and glaucoma that have the potential to define new treatment approaches and improve upon current patient care.”

Allergan will present 10 abstracts, including three paper and seven poster presentations (all noted in local Pacific Time):

Retina Paper Presentations:

  • Phase 2b Study of Brimonidine DDS: Potential Novel Treatment for Geographic Atrophy
    • Authors: Freeman W et al
    • Date and Time: Sunday, April 28, 3:15 – 3:30 PM 
  • Outcomes of AVF Treatment Switch in DME Patients in US Clinical Practice: Analysis of the AAO IRIS Database
    • Authors: Shih V et al
    • Date and Time: Tuesday, April 30, 4:00 – 4:15 PM
  • Phase 3 Evaluation of the Efficacy and Safety of Abicipar Compared with Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
    • Authors: Kunimoto D et al
    • Date and Time: Wednesday, May 1, 4:15 – 4:30 PM

Retina Poster Sessions:

  • Does Brimonidine DDS Reduce the Geographic Atrophy Lesion Perimeter Hyperautofluorescence Over Time?
    • Authors: Lewis A et al
    • Date and Time: Sunday, April 28, 1:00 – 2:45 PM
  • Cyto-/neuro-protective Effects of Brimonidine Drug Delivery System (DDS) in a Nonhuman Primate Progressive Retinal Degeneration Model of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
    • Authors: Rajagopalan L et al
    • Date and Time: Tuesday, April 30, 8:45 – 10:30 AM

Glaucoma Poster Sessions:

  • Effect of Sustained-Release Bimatoprost Implant (Bimatoprost SR) on Visual Field Mean Deviation in Patients with Glaucoma in a Phase 1/2 Clinical Trial
    • Authors: Rhee DJ et al
    • Date and Time: Monday, April 29, 4:00 – 5:45 PM
  • 12-month Efficacy and Safety of Brimonidine Tartrate 0.2%/Timolol 0.5% Ophthalmic Solution in Korean Patients with Primary Open-Angle and Normal-Tension GlaucomasThe KOCO Study
    • Authors: Park SW et al
    • Date and Time: Monday, April 29, 4:00 – 5:45 PM
  • Intraocular Pressure (IOP) Lowering Efficacy of Bimatoprost Sustained Release (Bim SR) in Dogs Pretreated with Selective Laser Trabeculoplasty (SLT)
    • Authors: Ghosn C et al
    • Date and Time: Tuesday, April 30, 11:45 AM – 1:30 PM
  • The effects of Selective Laser Trabeculoplasty (SLT) in Normotensive Beagle Dogs
    • Authors: Engles M et al
    • Date and Time: Tuesday, April 30, 11:45 AM – 1:30 PM
  • Patient Journey After Intensification of Topical Glaucoma Therapy ─ a US Claims-Based Analysis
    • Authors: Patel A et al
    • Date and Time: Wednesday, May 1, 8:15 – 10:00 AM

Related Content